Plain-English translation of NCT05230680 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing azacitidine combined with standard chemotherapy (called CHOP) for people with a specific rare type of T-cell lymphoma that hasn't been treated before. The study has two parts: first, doctors will find the right dose of azacitidine to use safely with the chemotherapy; then, they'll test whether this combination works well to treat the lymphoma.
This rare type of T-cell lymphoma is difficult to treat, and current standard treatments don't work well enough for many patients. Researchers believe adding this medication to existing chemotherapy might improve how well the treatment works.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the new medication combined with standard chemotherapy every 3 weeks. In the first part of the trial, doctors carefully increase the dose to find the safest level; in the second part, you would receive 6 cycles of treatment at the determined dose. After completing the main treatment, you would continue with additional medication injections every 4 weeks for about 3 months. The trial involves regular clinic visits for blood tests, infusions, and monitoring.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
South Korea
Phase
Safety & dosing / Early efficacy
Sponsor
Won Seog Kim
Enrollment target
~41 participants
Started
July 2022
Primary completion
December 2026
Age range
20 Years – 85 Years
Last updated on clinicaltrials.gov in October 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
kim wonseog, phD
Won Seog Kim
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.